<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="en">
  
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">MDM</journal-id>
      <journal-id journal-id-type="hwp">spmdm</journal-id>
      <journal-id journal-id-type="nlm-ta">Med Decis Making</journal-id>
      <journal-title>Medical Decision Making</journal-title>
      <issn pub-type="ppub">0272-989X</issn>
      <issn pub-type="epub">1552-681X</issn>
      <publisher>
        <publisher-name>SAGE Publications</publisher-name>
        <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.1177/0272989X13487604</article-id>
      <article-id pub-id-type="publisher-id">10.1177_0272989X13487604</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Evidence Synthesis for Decision Making 1</article-title>
        <subtitle>Introduction</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" xlink:type="simple">
          <name name-style="western">
            <surname>Dias</surname>
            <given-names>Sofia</given-names>
          </name>
          <degrees>PhD</degrees>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Welton</surname>
            <given-names>Nicky J.</given-names>
          </name>
          <degrees>PhD</degrees>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Sutton</surname>
            <given-names>Alex J.</given-names>
          </name>
          <degrees>PhD</degrees>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Ades</surname>
            <given-names>A. E.</given-names>
          </name>
          <degrees>PhD</degrees>
        </contrib>
      </contrib-group>
      <aff id="aff1-0272989X13487604">School of Social and Community Medicine, University of
        Bristol, Bristol, UK (SD, NJW, AEA)</aff>
      <aff id="aff2-0272989X13487604">Department of Health Sciences, University of Leicester,
        Leicester, UK (AJS)</aff>
      <author-notes>
        <corresp id="corresp1-0272989X13487604">Sofia Dias, School of Social and Community Medicine,
          University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK; e-mail:
            <email xlink:type="simple">s.dias@bristol.ac.uk</email>.</corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>7</month>
        <year>2013</year>
      </pub-date>
      <volume>33</volume>
      <issue>5</issue>
      <fpage>597</fpage>
      <lpage>606</lpage>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>6</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>1</day>
          <month>4</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/" xlink:type="simple">
          <p>This is an open-access article distributed under the terms of the Creative
            Commons Attribution License, which permits non-commercial use, distribution,
            and reproduction in any medium, provided the original work is properly
            cited.</p>
        </license>
      </permissions>
      <abstract>
        <p>We introduce the series of 7 tutorial papers on evidence synthesis methods for decision
          making, based on the Technical Support Documents in Evidence Synthesis prepared for the
          National Institute for Health and Clinical Excellence (NICE) Decision Support Unit.
          Although oriented to NICE’s Technology Appraisal process, which examines new
          pharmaceutical products in a cost-effectiveness framework, the methods presented
          throughout the tutorials are equally relevant to clinical guideline development and to
          comparisons between medical devices, or public health interventions. Detailed guidance is
          given on how to use the other tutorials in the series, which propose a single evidence
          synthesis framework that covers fixed and random effects models, pairwise meta-analysis,
          indirect comparisons, and network meta-analysis, and where outcomes expressed in several
          different reporting formats can be analyzed without recourse to normal approximations. We
          describe the principles of evidence synthesis required by the 2008 revision of the NICE
          Guide to the Methods of Technology Appraisal and explain how the approach proposed in
          these tutorials was designed to conform to those requirements. We finish with some
          suggestions on how to present the evidence, the synthesis methods, and the results.</p>
      </abstract>
      <kwd-group>
        <kwd>cost-effectiveness analysis</kwd>
        <kwd>Bayesian meta-analysis</kwd>
        <kwd>systematic reviews</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>This paper is the first of 7 tutorial papers on evidence synthesis methods in decision
      making, which are based on the Technical Support Documents (TSDs) in Evidence Synthesis
      prepared for the National Institute for Health and Clinical Excellence (NICE) Decision Support
      Unit and available from <ext-link ext-link-type="uri" xlink:href="http://www.nicedsu.org.uk/" xlink:type="simple">http://www.nicedsu.org.uk/</ext-link>. The TSDs are intended to support the appraisals
      process, which examines new pharmaceutical products in a cost-effectiveness
          framework,<sup><xref ref-type="bibr" rid="bibr1-0272989X13487604">1</xref>,<xref ref-type="bibr" rid="bibr2-0272989X13487604">2</xref></sup> by explaining the requirements
      in the 2008 revision of the NICE Guide to the Methods of Technology Appraisal,<sup><xref ref-type="bibr" rid="bibr3-0272989X13487604">3</xref></sup> by showing how analyses can be
      implemented so that they have the required properties, and by giving concrete, worked
      examples. Although aimed at those making, reviewing, and appraising submissions to NICE, the
      TSDs do not attempt to “prescribe” the form that analyses must take or the methods that must
      be used. Any methods fulfilling the required properties are valid. It should be noted that the
      2008 methods guide will shortly be replaced by the 2013 revision, currently only available as
      a draft for consultation. The main changes in this draft, which have been largely anticipated
      by the TSDs, relate to trial inclusion criteria and presentation of the evidence and
          results.<sup><xref ref-type="bibr" rid="bibr4-0272989X13487604">4</xref></sup></p>
    <p>This series of tutorial papers is intended primarily to introduce the proposed Bayesian
      evidence synthesis methods to a wider audience and to address evidence synthesis issues
      concerning the relative and absolute efficacy of interventions. In this introductory paper, we
      suggest how to use the tutorial series in practice, set out the key properties of evidence
      synthesis for decision making in NICE Technical Appraisals, and explain the reasons why the
      proposed approach is particularly suited to this context. We finish with some suggestions on
      how to present the evidence, the synthesis methods, and the results.</p>
    <p>The methods used in NICE Technical Appraisals have tended to set a benchmark for methods used
      in other work that NICE undertakes. For example, the methods advocated in the 2008 Guide to
      Methods of Technology Appraisal are referred to in NICE’s 2009 Clinical Guidelines
          Manual,<sup><xref ref-type="bibr" rid="bibr5-0272989X13487604">5</xref></sup> and the 2012
          update<sup><xref ref-type="bibr" rid="bibr6-0272989X13487604">6</xref></sup> refers
      directly to TSDs on which this tutorial series is based. Thus, the methods proposed are
      equally relevant to clinical guideline development and to comparisons between medical devices
      or public health interventions. The series does not, however, cover questions arising from the
      synthesis of data on diagnostic test performance<sup><xref ref-type="bibr" rid="bibr7-0272989X13487604">7</xref></sup> or general synthesis of epidemiological
          data,<sup><xref ref-type="bibr" rid="bibr8-0272989X13487604">8</xref></sup> largely
      because issues in diagnostic technologies, screening, and public health are outside the remit
      of the NICE appraisals process.</p>
    <sec id="section1-0272989X13487604">
      <title>Using the Tutorial Series</title>
      <p>The tutorial series can be used as a learning tool for anyone wishing to carry out evidence
        synthesis in the context of decision making, whether on clinical grounds or for
        cost-effectiveness. The methods can clearly be extended further into comparisons that set
        benefits against side effects and analyses based on multicriteria decision
            analysis.<sup><xref ref-type="bibr" rid="bibr9-0272989X13487604">9</xref></sup></p>
      <p>The second tutorial in this series<sup><xref ref-type="bibr" rid="bibr10-0272989X13487604">10</xref></sup> sets out the proposed Bayesian framework and provides an extensive
        appendix with WinBUGS code for the core pairwise and Network Meta-analysis (NMA) model, with
        worked examples for various types of outcomes. This includes details of how to set up data,
        obtain key outputs, and present and interpret the results. Because of the modular nature of
        the code, once readers are familiar with the core NMA model for binomial data and how it
        needs to be changed for other data types, they will be able to adapt the code in the
        remaining tutorials (e.g., for meta-regression<sup><xref ref-type="bibr" rid="bibr11-0272989X13487604">11</xref></sup> or inconsistency checking<sup><xref ref-type="bibr" rid="bibr12-0272989X13487604">12</xref></sup>) to suit their own data.
          <xref ref-type="table" rid="table1-0272989X13487604">Table 1</xref> sets out the examples
        and data sets presented in the other tutorials in this series and summarizes what can be
        learned from studying them. However, before one attempts the Bayesian evidence syntheses
        proposed, a thorough grounding in Bayesian statistics and the use of WinBUGS<sup><xref ref-type="bibr" rid="bibr13-0272989X13487604">13</xref></sup> is required. The WinBUGS
            manual<sup><xref ref-type="bibr" rid="bibr14-0272989X13487604">14</xref></sup> and its
        online tutorial, particularly the “Blocker” example in the Help menu, as well as many other
        examples available elsewhere,<sup><xref ref-type="bibr" rid="bibr15-0272989X13487604">15</xref>,<xref ref-type="bibr" rid="bibr16-0272989X13487604">16</xref></sup> are key
        resources, as is an introduction to Bayesian methods.<sup><xref ref-type="bibr" rid="bibr16-0272989X13487604">16</xref>,<xref ref-type="bibr" rid="bibr17-0272989X13487604">17</xref></sup> Proper attention to the technical aspects
        of WinBUGS, such as convergence and burn-in, is essential.</p>
      <table-wrap id="table1-0272989X13487604" position="float">
        <label>Table 1</label>
        <caption>
          <p>List of Examples Used in the Tutorial Papers in This Series, with Details on the Type
            of Analysis Used and What Readers Can Learn from Each of the Examples</p>
        </caption>
        <graphic alt-version="no" alternate-form-of="table1-0272989X13487604" position="float" xlink:href="10.1177_0272989X13487604-table1.tif" xlink:type="simple"/>
        <table>
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" colspan="1" rowspan="1">Example</th>
              <th align="center" colspan="1" rowspan="1">Outcome Type</th>
              <th align="center" colspan="1" rowspan="1">Tutorial(s) in Which This Example Appears</th>
              <th align="center" colspan="1" rowspan="1">Type of Analysis</th>
              <th align="center" colspan="1" rowspan="1">What Readers Will Learn</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td colspan="1" rowspan="1">Blocker<sup><xref ref-type="bibr" rid="bibr14-0272989X13487604">14</xref>,<xref ref-type="bibr" rid="bibr31-0272989X13487604">31</xref></sup></td>
              <td colspan="1" rowspan="1">Binomial</td>
              <td colspan="1" rowspan="1">GLM framework<sup><xref ref-type="bibr" rid="bibr10-0272989X13487604">10</xref></sup></td>
              <td colspan="1" rowspan="1">Pairwise meta-analysis (fixed and random effects)</td>
              <td colspan="1" rowspan="1">Core code for NMA, assessing model fit and model choice (fixed v. random effects);
                how to set up binomial data for analysis; obtaining and interpreting results.</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Dietary fat<sup><xref ref-type="bibr" rid="bibr32-0272989X13487604">32</xref></sup></td>
              <td colspan="1" rowspan="1">Poisson</td>
              <td colspan="1" rowspan="1">GLM framework<sup><xref ref-type="bibr" rid="bibr10-0272989X13487604">10</xref></sup></td>
              <td colspan="1" rowspan="1">NMA (fixed and random effects)</td>
              <td colspan="1" rowspan="1">Code for NMA with Poisson data; how to set up data for analysis; obtaining and
                interpreting results.</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Diabetes<sup><xref ref-type="bibr" rid="bibr33-0272989X13487604">33</xref></sup></td>
              <td colspan="1" rowspan="1">Binomial with varying follow-up times</td>
              <td colspan="1" rowspan="1">GLM framework<sup><xref ref-type="bibr" rid="bibr10-0272989X13487604">10</xref></sup></td>
              <td colspan="1" rowspan="1">NMA (fixed and random effects)</td>
              <td colspan="1" rowspan="1">Code for NMA with binomial data on rates; how to set up data for analysis;
                obtaining and interpreting results</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Schizophrenia<sup><xref ref-type="bibr" rid="bibr28-0272989X13487604">28</xref></sup></td>
              <td colspan="1" rowspan="1">Multinomial with competing risks</td>
              <td colspan="1" rowspan="1">GLM framework<sup><xref ref-type="bibr" rid="bibr10-0272989X13487604">10</xref></sup></td>
              <td colspan="1" rowspan="1">NMA (fixed and random effects)</td>
              <td colspan="1" rowspan="1">Code for NMA with competing risks data; how to set up data for analysis; obtaining
                and interpreting results.</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Parkinson’s<sup><xref ref-type="bibr" rid="bibr34-0272989X13487604">34</xref></sup></td>
              <td colspan="1" rowspan="1">Normal (continuous) data with multiple reporting formats</td>
              <td colspan="1" rowspan="1">GLM framework<sup><xref ref-type="bibr" rid="bibr10-0272989X13487604">10</xref></sup></td>
              <td colspan="1" rowspan="1">NMA (fixed and random effects); shared parameter model</td>
              <td colspan="1" rowspan="1">Code for NMA with normal data presented as arm-based means, relative effects, or a
                combination of these 2 formats; how to set up data for analysis; obtaining and
                interpreting results.</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Psoriasis<sup><xref ref-type="bibr" rid="bibr35-0272989X13487604">35</xref></sup></td>
              <td colspan="1" rowspan="1">Multinomial with multiple, ordered outcomes</td>
              <td colspan="1" rowspan="1">GLM framework<sup><xref ref-type="bibr" rid="bibr10-0272989X13487604">10</xref></sup></td>
              <td colspan="1" rowspan="1">NMA (fixed and random effects)</td>
              <td colspan="1" rowspan="1">Code for NMA with ordered data; how to set up data for analysis; obtaining and
                interpreting results.</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Statins<sup><xref ref-type="bibr" rid="bibr36-0272989X13487604">36</xref></sup></td>
              <td colspan="1" rowspan="1">Binomial</td>
              <td colspan="1" rowspan="1">Heterogeneity and meta-regression<sup><xref ref-type="bibr" rid="bibr11-0272989X13487604">11</xref></sup></td>
              <td colspan="1" rowspan="1">Pairwise meta-analysis with subgroups</td>
              <td colspan="1" rowspan="1">Code for NMA with subgroups; obtaining and interpreting results.</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Rheumatoid arthritis (certolizumab)<sup><xref ref-type="bibr" rid="bibr37-0272989X13487604">37</xref></sup></td>
              <td colspan="1" rowspan="1">Binomial</td>
              <td colspan="1" rowspan="1">Heterogeneity and meta-regression<sup><xref ref-type="bibr" rid="bibr11-0272989X13487604">11</xref></sup></td>
              <td colspan="1" rowspan="1">NMA with continuous covariate; NMA with adjustment for baseline risk</td>
              <td colspan="1" rowspan="1">Code for NMA with continuous covariate, including baseline risk; obtaining and
                interpreting results. The Appendix includes notes on how to include an informative
                prior on the heterogeneity, for sparse data.</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Smoking cessation<sup><xref ref-type="bibr" rid="bibr38-0272989X13487604">38</xref>,<xref ref-type="bibr" rid="bibr39-0272989X13487604">39</xref></sup></td>
              <td colspan="1" rowspan="1">Binomial</td>
              <td colspan="1" rowspan="1">Inconsistency<sup><xref ref-type="bibr" rid="bibr12-0272989X13487604">12</xref></sup></td>
              <td colspan="1" rowspan="1">Unrelated mean effects model (random effects)</td>
              <td colspan="1" rowspan="1">Code for unrelated mean effects model to detect inconsistency in a random effects
                NMA; obtaining and interpreting results.</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">Baseline model<sup><xref ref-type="bibr" rid="bibr18-0272989X13487604">18</xref></sup></td>
              <td colspan="1" rowspan="1">Synthesis of baseline effects (random effects model); NMA with joint baseline
                modeling (random effects)</td>
              <td colspan="1" rowspan="1">Code for joint and separate synthesis of baseline and relative effects with
                predictive distributions; using the results.</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Thrombolytic treatments<sup><xref ref-type="bibr" rid="bibr40-0272989X13487604">40</xref>,<xref ref-type="bibr" rid="bibr41-0272989X13487604">41</xref></sup></td>
              <td colspan="1" rowspan="1">Binomial</td>
              <td colspan="1" rowspan="1">Inconsistency<sup><xref ref-type="bibr" rid="bibr12-0272989X13487604">12</xref></sup></td>
              <td colspan="1" rowspan="1">Unrelated mean effects model (fixed effects)</td>
              <td colspan="1" rowspan="1">Code for unrelated mean effects model to detect inconsistency in a fixed effects
                NMA; obtaining and interpreting results.</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="table-fn1-0272989X13487604">
            <p>Note: NMA = network meta-analysis.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Having completed these preliminaries, readers will be ready to start analyzing their own
        data set. We strongly recommend starting with the simplest analysis, a pairwise
        meta-analysis, before attempting an NMA, using the code provided.<sup><xref ref-type="bibr" rid="bibr10-0272989X13487604">10</xref></sup> Once this has been mastered, one can step
        up to NMA and then to shared parameter models.<sup><xref ref-type="bibr" rid="bibr10-0272989X13487604">10</xref></sup> The methods for meta-regression including
        bias adjustment and inconsistency checking, described in the third<sup><xref ref-type="bibr" rid="bibr11-0272989X13487604">11</xref></sup> and fourth<sup><xref ref-type="bibr" rid="bibr12-0272989X13487604">12</xref></sup> tutorials in this series, can be attempted
        next, but at each stage it is essential that readers monitor all relevant parameters (nodes)
        and make sure they understand every aspect of the outputs and procedures for checking
        convergence before moving on to the next stage.</p>
      <p>Readers interested in evidence synthesis for the baseline natural history model and in
        using the results of the synthesis in a probabilistic cost-effectiveness analysis (CEA)
        should also consult the fifth and sixth tutorials in this series.<sup><xref ref-type="bibr" rid="bibr18-0272989X13487604">18</xref>,<xref ref-type="bibr" rid="bibr19-0272989X13487604">19</xref></sup></p>
      <p>All readers, whether experienced or not, may benefit from the checklist,<sup><xref ref-type="bibr" rid="bibr20-0272989X13487604">20</xref></sup> as this sets out what
        journal reviewers and the general reader are likely to question.</p>
    </sec>
    <sec id="section2-0272989X13487604">
      <title>Evidence Synthesis in NICE’s Guide to the Methods of Technology Appraisal</title>
      <sec id="section3-0272989X13487604">
        <title>Principles of Evidence-Based Decision Making and Distributive Justice</title>
        <p>The 2008 methods guide, like all other documents and procedures at NICE, follows a set of
          basic principles. Some of these are derived from the legislation governing NICE’s
          establishment, others from one of its key foundational documents concerning social value
              judgments.<sup><xref ref-type="bibr" rid="bibr21-0272989X13487604">21</xref></sup>
          This sets out the principles of evidence-based decision making and directs that NICE must
          consider the “broad balance of clinical benefits and costs.” It also spells out principles
          of distributive justice. What emerges from these basic principles is a need to allocate
          scarce resources fairly, in a way that gives patients “equal access” to care, regardless
          of whether they have cancer, arthritis, or any other condition. This, in turn, leads to
          CEA based on optimizing expected net benefit, seen as monetized health gain minus
          cost.</p>
        <p>The emphasis on consistency of approach, both across conditions and across appraisals,
          has implications for evidence synthesis, which we have interpreted as a requirement for a
          uniform approach to synthesis, that can be applied to trials in any area of medicine. This
          underlies our adoption of a generalized linear modeling (GLM) framework,<sup><xref ref-type="bibr" rid="bibr10-0272989X13487604">10</xref></sup> with a uniform set of
          criteria for model fit, model selection, and model diagnostics,<sup><xref ref-type="bibr" rid="bibr10-0272989X13487604">10</xref><xref ref-type="bibr" rid="bibr11-0272989X13487604"/>-<xref ref-type="bibr" rid="bibr12-0272989X13487604">12</xref></sup> regardless of the type of outcome (continuous, rate, proportion,
          etc.) that is recorded and reported. It also leads to “shared parameter models,”<sup><xref ref-type="bibr" rid="bibr10-0272989X13487604">10</xref></sup> because the synthesis
          method and results should not be affected by a trial’s reporting format. For example, one
          should be able to derive the same estimates whether trials report mean treatment
          differences or arm-based summaries, or whether events and time at risk or numbers of
          patients reaching end points are reported. Similarly, and for the same reason, it leads us
          to more complex models for synthesis of multiple outcomes<sup><xref ref-type="bibr" rid="bibr10-0272989X13487604">10</xref>,<xref ref-type="bibr" rid="bibr19-0272989X13487604">19</xref></sup> that may be reported differently in
          different trials.</p>
      </sec>
      <sec id="section4-0272989X13487604">
        <title>Transparency</title>
        <p>The social value document<sup><xref ref-type="bibr" rid="bibr21-0272989X13487604">21</xref></sup> also emphasizes procedural justice: Recommendations must be based on
          a transparent process, one that is open to challenge and revision. Related to this, NICE
          follows a principle of “inclusiveness”: different stakeholders, whether manufacturers,
          patients, or health care professionals, must all have an opportunity to comment on the
          scope of the recommendations and to challenge them. Comments must be responded to, and
          there are provisions for appeal. Although courts have not challenged the appraisal
          committee’s scientific reasoning or its decisions, they have intervened to insist that the
          basis for the decisions be fully explained. This degree of accountability and
          transparency, as well as the need for consistency between appraisals, has led us to
          advocate a relatively limited set of modeling options,<sup><xref ref-type="bibr" rid="bibr10-0272989X13487604">10</xref>,<xref ref-type="bibr" rid="bibr11-0272989X13487604">11</xref>,<xref ref-type="bibr" rid="bibr18-0272989X13487604">18</xref></sup> some criteria for choosing between
              them,<sup><xref ref-type="bibr" rid="bibr10-0272989X13487604">10</xref></sup> and
          liberal use of sensitivity analysis when there are insufficient grounds for choosing one
          option over another.<sup><xref ref-type="bibr" rid="bibr20-0272989X13487604">20</xref></sup> Although there is nothing to prevent those making submissions to NICE
          from using other methods if this can be reasonably justified, the fact that the apparatus
          for choosing one model over another can be made uniform across different types of data and
              models<sup><xref ref-type="bibr" rid="bibr10-0272989X13487604">10</xref></sup> is an
          essential prerequisite to meet requirements of transparency and consistency.</p>
      </sec>
      <sec id="section5-0272989X13487604">
        <title>Role of Indirect Comparisons and Network Meta-analysis</title>
        <p>The 2008 methods guide sets out the role of indirect comparisons and NMA in a somewhat
          disconnected, but consistent, way. The main principle is that “direct” evidence is
          strongly preferred, which means that the NICE “reference case” or default analysis should
          be based only on trials directly comparing the new treatments with standard comparators.
          Then analyses based on indirect evidence, or combined direct and indirect evidence (i.e.,
          mixed treatment comparison or NMA), can be presented as an additional analysis.</p>
        <p>In practice, it is well recognized that this advice can only be precisely applied where
          the decision facing the Appraisals Committee is between just 2 treatments. As soon as
          there are 3 or more treatments in the same decision problem, a method is required that
          constructs a coherent set of comparisons based on all the available trial evidence, ruling
          out a reliance on purely “direct” comparisons in modeling (unless all trials have arms for
          all the relevant treatments). This is precisely what NMA models are designed to
          achieve.</p>
      </sec>
      <sec id="section6-0272989X13487604">
        <title>Relation between Pairwise and Network Meta-analysis</title>
        <p>NICE has 2 appraisal processes, multiple- and single-technology appraisal (MTA, STA). In
          an MTA, a set of competing new products are compared with each other and with standard
          comparators, whereas in an STA a single new product is under scrutiny. Although an NMA is
          almost always used in MTAs, STAs may be based on pairwise synthesis or NMA. However, the
          methods guide requires that the methods of assessment be the same. The evidence synthesis
          models and the WinBUGS software for implementing them presented throughout this tutorial
              series<sup><xref ref-type="bibr" rid="bibr10-0272989X13487604">10</xref>,<xref ref-type="bibr" rid="bibr11-0272989X13487604">11</xref></sup> have precisely this
          property: The software will run either type of analysis without distinction, and the
          pairwise model is simply a special case of the NMA model in which only 2 treatments are
          being compared. This is not necessarily the case in other models, or software, for NMA.
          The Lumley model<sup><xref ref-type="bibr" rid="bibr22-0272989X13487604">22</xref></sup>
          for NMA cannot be run on pairwise meta-analysis or on indirect comparisons, nor in its
          published form can it deal correctly with trials comparing more than 2 treatments. These
          are serious shortcomings, as manufacturers, clinicians, and decision makers will want to
          be assured that there is a single, fair way of estimating treatment effects, regardless of
          the structure of the evidence.</p>
      </sec>
      <sec id="section7-0272989X13487604">
        <title>Trial Inclusion and Exclusion Criteria in Construction of the Comparison
          Network</title>
        <p>The 2008 methods guide explicitly allows submissions to present indirect treatment
          comparisons that include treatments that are not part of the decision problem, if their
          inclusion makes a “connected” network of randomized trials. Beyond that, however, little
          guidance is given on the size of a network or its construction. A connected network is one
          in which a direct or indirect comparison can be made between every treatment, based on
          randomized data, therefore allowing relative effects of every treatment relative to every
          other to be estimated (<xref ref-type="fig" rid="fig1-0272989X13487604">Figure 1</xref>).
          The draft of the 2013 revision to the methods guide<sup><xref ref-type="bibr" rid="bibr4-0272989X13487604">4</xref></sup> suggests the following simple rules for
          network construction. First, in <xref ref-type="fig" rid="fig2-0272989X13487604">Figure
            2a</xref>, three treatments A, B, and C are of interest but an additional treatment X
          has been included because there are trials comparing A v. X and C v. X, thus forming a
          connected network. If treatments could also have been connected by the addition of A v. Y
          and C v. Y trials, then <italic>both</italic> X and Y should be added to the comparator
          set (<xref ref-type="fig" rid="fig2-0272989X13487604">Figure 2b</xref>). Next, every trial
          on the target population involving 2 or more members of the comparator set should be
          included. These rules are in the spirit of the preference for direct evidence and both
          limit the network to a minimum and identify a unique set of trials. However, this means
          that trial searching and treatment inclusion decisions may become an iterative process
          when the initial treatment network is not connected.</p>
        <fig id="fig1-0272989X13487604" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Disconnected treatment network. Lines represent a comparison of the connected
              treatments in at least one trial. The network formed by treatments A, B, and C is not
              connected to the network formed by treatments X and Y.</p>
          </caption>
          <graphic alt-version="no" position="float" xlink:href="10.1177_0272989X13487604-fig1.tif" xlink:type="simple"/>
        </fig>
        <fig id="fig2-0272989X13487604" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Treatment network in which the treatments relevant for the decision and for synthesis
              differ. Lines represent a comparison of the connected treatments in at least one
              trial. Treatments relevant to the decision are in bold. (a) Treatment X has been added
              to the synthesis because it links treatment C to the rest of the network (dashed
              lines); (b) Treatment Y also links treatment C to the network and needs to be added to
              the synthesis (long-dashed lines).</p>
          </caption>
          <graphic alt-version="no" position="float" xlink:href="10.1177_0272989X13487604-fig2.tif" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="section8-0272989X13487604">
        <title>Bias in Randomized and Nonrandomized Evidence</title>
        <p>The 2008 methods guide recognizes that randomized evidence is subject to potential biases
          regarding its internal and external validity and that nonrandomized evidence, which may be
          needed if trial evidence is weak, is even more vulnerable to these problems. At the same
          time it calls for all the available evidence to be integrated. This opens the possibility
          of various approaches to bias and covariate adjustment as part of the synthesis, which are
          described in the third tutorial in this series.<sup><xref ref-type="bibr" rid="bibr11-0272989X13487604">11</xref></sup></p>
      </sec>
      <sec id="section9-0272989X13487604">
        <title>Modeling Natural History and Relative Treatment Effects</title>
        <p>The 2008 methods guide envisages a “baseline” model that represents the patient’s natural
          history and care pathway on a standard treatment (e.g., usual care or placebo), to which
          relative treatment effects based on randomized evidence will be applied. It is envisaged
          that the natural history model will often be based on nonrandomized evidence and that
          there will be a need to extrapolate beyond the trial outcomes, as the default NICE
          base-case model requires lifetime benefits and costs. This kind of modeling approach, and
          relevant forms of synthesis, are described in the fifth tutorial in this series.<sup><xref ref-type="bibr" rid="bibr18-0272989X13487604">18</xref></sup></p>
      </sec>
      <sec id="section10-0272989X13487604">
        <title>Subgroups and Meta-regression</title>
        <p>Both effectiveness and cost-effectiveness of treatments can differ by patient subgroup,
          and this may occur because of differences in natural history or because of differences in
          relative treatment effects. Models based on differences in relative treatment
              effects<sup><xref ref-type="bibr" rid="bibr11-0272989X13487604">11</xref></sup> are
          permitted by the methods guide but need to be supported by a priori biological
          plausibility and statistical evidence for interactions and must be safeguarded against
          data dredging. Post hoc identification of subgroups is not precluded, but identification
          at the scoping stage is preferred. Individual participant data (IPD) are preferred for
          estimation of subgroup effects, and we describe meta-regression methods that can be used
          with aggregate data, individual data, or a combination of both.<sup><xref ref-type="bibr" rid="bibr11-0272989X13487604">11</xref></sup></p>
        <p>Any proposed subgroup differences in general natural history require full documentation
          and justification although they present no additional synthesis or modeling challenges.
          However, NICE’s obligations under human rights, discrimination, and equality legislation
          prevent it from issuing guidance that denies patients access to treatments on the basis of
          age, gender, race, disability, socioeconomic status, or geographical location, except
          where these factors directly affect the efficacy of treatment. This rules out, for
          example, approval of a treatment in 65-year-olds but not in 75-year-olds just because the
          expected health gain is less in the latter group.</p>
      </sec>
      <sec id="section11-0272989X13487604">
        <title>Uncertainty: Analytic Methods Compatible with Probabilistic Cost-Effectiveness
          Analysis</title>
        <p>It is essential that evidence synthesis methods are fully compatible with the
          probabilistic CEA, as this is the NICE reference case. The methods guide emphasizes the
          need for correctly propagating parameter uncertainty and parameter correlation structure
          through to decision uncertainty, as the latter is a major consideration in appraisal
          committee decisions. The syntheses methods proposed throughout this series of papers,
          based on Bayesian posterior simulation from joint parameter distributions, are
          specifically designed to meet these requirements. However, other methods that also meet
          the requirements, at least under some circumstances, are described in the sixth paper in
          this series.<sup><xref ref-type="bibr" rid="bibr19-0272989X13487604">19</xref></sup></p>
      </sec>
      <sec id="section12-0272989X13487604">
        <title>Sensitivity Analysis</title>
        <p>Throughout the methods guide there is an emphasis on the use of sensitivity analyses in
          the presence of structural uncertainties of different types. Of particular relevance in
          evidence synthesis are the inclusion or exclusion of specific trials in an evidence
          network; the choice between fixed and random effects models, especially when this cannot
          be decided on the basis of goodness of fit; and the choice between models with and without
          various adjustments. Suggestions about the circumstances in which sensitivity analyses
          should be presented are mentioned throughout the tutorial series and also in the
          reviewer’s checklist.<sup><xref ref-type="bibr" rid="bibr20-0272989X13487604">20</xref></sup></p>
      </sec>
    </sec>
    <sec id="section13-0272989X13487604" sec-type="methods">
      <title>Presentation of the Evidence, Results, and Methods of Evidence Synthesis</title>
      <p>There is a need to present the input data for the CEA, the summary statistics of the
        parameters used in it, and the incremental costs and effects. The 2008 methods guide gives
        little detail on how to do this, but we suggest that when there are more than 2 treatments
        in the comparator set for synthesis, it is helpful to show a network diagram (such as <xref ref-type="fig" rid="fig2-0272989X13487604">Figure 2</xref>). Software for automatically
        drawing such diagrams is available as stand-alone programs with multiple capabilities (e.g.,
            Pajek<sup><xref ref-type="bibr" rid="bibr23-0272989X13487604">23</xref></sup>) or as
        packages and routines developed for R<sup><xref ref-type="bibr" rid="bibr24-0272989X13487604">24</xref></sup> among other programs.</p>
      <p>Further refinements in network diagrams that can be implemented in various software include
        1) adding the number of studies making that comparison to each connecting line (<xref ref-type="fig" rid="fig3-0272989X13487604">Figure 3</xref>) and 2) having the thickness of
        the connecting lines reflect the number of trials on that contrast and the size of the
        vertices reflect the number of patients randomized to that treatment.<sup><xref ref-type="bibr" rid="bibr25-0272989X13487604">25</xref></sup> A second useful
        presentation of the data is as a table of the sort shown here in <xref ref-type="table" rid="table2-0272989X13487604">Table 2</xref>. It is also convenient to add columns
        indicating trial-level covariate values or whether IPD are available.</p>
      <fig id="fig3-0272989X13487604" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Parkinson network.<sup><xref ref-type="bibr" rid="bibr34-0272989X13487604">34</xref></sup> Each edge represents a treatment, and connecting lines indicate pairs
            of treatments that have been directly compared in randomized trials. The numbers on the
            lines indicate the numbers of trials making that comparison, and the numbers in brackets
            represent the treatment coding used in the analysis.</p>
        </caption>
        <graphic alt-version="no" position="float" xlink:href="10.1177_0272989X13487604-fig3.tif" xlink:type="simple"/>
      </fig>
      <table-wrap id="table2-0272989X13487604" position="float">
        <label>Table 2</label>
        <caption>
          <p>Certolizumab Pegol (CZP) for Rheumatoid Arthritis</p>
        </caption>
        <graphic alt-version="no" alternate-form-of="table2-0272989X13487604" position="float" xlink:href="10.1177_0272989X13487604-table2.tif" xlink:type="simple"/>
        <table>
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" colspan="1" rowspan="1">Study Name<sup><xref ref-type="table-fn" rid="table-fn3-0272989X13487604">a</xref></sup></th>
              <th align="center" colspan="1" rowspan="1">Placebo</th>
              <th align="center" colspan="1" rowspan="1">CZP</th>
              <th align="center" colspan="1" rowspan="1">Adalimumab</th>
              <th align="center" colspan="1" rowspan="1">Etanercept</th>
              <th align="center" colspan="1" rowspan="1">Infliximab</th>
              <th align="center" colspan="1" rowspan="1">Rituximab</th>
              <th align="center" colspan="1" rowspan="1">Tocilizumab</th>
              <th align="center" colspan="1" rowspan="1">Mean Disease Duration (Years)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td colspan="1" rowspan="1">Kim 2007</td>
              <td colspan="1" rowspan="1">9/63</td>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">28/65</td>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">6.85</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">DE019</td>
              <td colspan="1" rowspan="1">19/200</td>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">81/207</td>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">10.95</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">ARMADA</td>
              <td colspan="1" rowspan="1">5/62</td>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">37/67</td>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">11.65</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">RAPID 1</td>
              <td colspan="1" rowspan="1">15/199</td>
              <td colspan="1" rowspan="1">146/393</td>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">6.15</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">RAPID 2</td>
              <td colspan="1" rowspan="1">4/127</td>
              <td colspan="1" rowspan="1">80/246</td>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">5.85</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">START</td>
              <td colspan="1" rowspan="1">33/363</td>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">110/360</td>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">8.1</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">ATTEST</td>
              <td colspan="1" rowspan="1">22/110</td>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">61/165</td>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">7.85</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Abe 2006<sup><xref ref-type="table-fn" rid="table-fn4-0272989X13487604">b</xref></sup></td>
              <td colspan="1" rowspan="1">0/47</td>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">15/49</td>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">8.3</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Weinblatt 1999</td>
              <td colspan="1" rowspan="1">1/30</td>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">23/59</td>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">13</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Strand 2006</td>
              <td colspan="1" rowspan="1">5/40</td>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">5/40</td>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">11.25</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">CHARISMA<sup><xref ref-type="table-fn" rid="table-fn4-0272989X13487604">b</xref></sup></td>
              <td colspan="1" rowspan="1">14/49</td>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">26/50</td>
              <td colspan="1" rowspan="1">0.915</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">OPTION</td>
              <td colspan="1" rowspan="1">22/204</td>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1"/>
              <td colspan="1" rowspan="1">90/205</td>
              <td colspan="1" rowspan="1">7.65</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="table-fn2-0272989X13487604">
            <p>Note: Number of patients achieving ACR50 at 6 months, out of the total number of
              patients, in 12 trials comparing 6 treatments with placebo, and mean disease duration
              (in years) for patients in each trial. Blank cells indicate that the treatment was not
              compared in that trial. All trial arms had methotrexate in addition to the placebo or
              active treatment.</p>
          </fn>
          <fn id="table-fn3-0272989X13487604">
            <label>a.</label>
            <p>For study references, see Reference 37 in this article.</p>
          </fn>
          <fn id="table-fn4-0272989X13487604">
            <label>b.</label>
            <p>ACR50 at 3 months.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Similarly, in the interests of transparency, reviewers and general readers must be provided
        with sufficient information to allow them to reproduce the analyses, if they had access to
        the data. If possible, journal citations for the precise model of the data being assumed,
        and/or citation of the source of software code, must be provided. Otherwise the statistical
        model for the synthesis should be set out fully in algebraic form and the software code used
        for the synthesis should be annotated and made available, along with the data used. When
        confidentiality requirements prevent the data from being released, a dummy data set with the
        same structure as the original should be provided.</p>
      <p>A clear discussion of the underlying statistical and clinical assumptions implied by the
        model, and their impact on the final decision, should also be included. In particular,
        reasons for choosing to model the outcomes on a particular scale (e.g., odds ratio, hazard
        ratio, risk difference etc.) and the assumptions implied in any transformation from the
        relative to the absolute effects should be clearly presented.<sup><xref ref-type="bibr" rid="bibr10-0272989X13487604">10</xref>,<xref ref-type="bibr" rid="bibr18-0272989X13487604">18</xref></sup> Transparency also requires that the choice
        of statistical model (e.g., fixed or random effects) and the use of an NMA, bias adjustment,
        or meta-regression be justified on statistical and/or clinical grounds.<sup><xref ref-type="bibr" rid="bibr10-0272989X13487604">10</xref><xref ref-type="bibr" rid="bibr11-0272989X13487604"/>-<xref ref-type="bibr" rid="bibr12-0272989X13487604">12</xref></sup></p>
      <p>Although the parameters required by the CEA tend to be the absolute treatment effects of
        each treatment,<sup><xref ref-type="bibr" rid="bibr18-0272989X13487604">18</xref></sup> it
        is essential to present both the relative treatment effects, which are the outputs from the
        evidence synthesis, and the absolute effects on which the CEA is based. It is important for
        those reviewing and evaluating submissions that there is absolute clarity and transparency
        about exactly what relative efficacies between treatments are being assumed and exactly what
        absolute effects are going forward into the CEA. This can be achieved in a number of ways.
        Perhaps the simplest method is a table of the mean treatment effect with 95% credible
        interval (CrI) of every treatment relative to placebo or to a standard comparator. <xref ref-type="table" rid="table3-0272989X13487604">Table 3</xref> gives an example of the
        relative and absolute mean lost work-time reduction in patients given 4 dopamine agonists
        and placebo as adjunct therapy for Parkinson’s disease.<sup><xref ref-type="bibr" rid="bibr10-0272989X13487604">10</xref></sup> The treatment network is presented in
          <xref ref-type="fig" rid="fig3-0272989X13487604">Figure 3</xref>.</p>
      <table-wrap id="table3-0272989X13487604" position="float">
        <label>Table 3</label>
        <caption>
          <p>Parkinson’s Example<sup><xref ref-type="bibr" rid="bibr34-0272989X13487604">34</xref></sup>: Posterior Mean (), Standard Deviation (<italic>s</italic>), and 95%
            Credible Interval (CrI) of the Mean Lost Work-Time Reduction for the Fixed Effects
            Models for the Treatment Effects Relative to Placebo, and Absolute Mean Lost Work-Time
            Reduction for Placebo and All Treatments</p>
        </caption>
        <graphic alt-version="no" alternate-form-of="table3-0272989X13487604" position="float" xlink:href="10.1177_0272989X13487604-table3.tif" xlink:type="simple"/>
        <table>
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th colspan="1" rowspan="1"/>
              <th colspan="1" rowspan="1"/>
              <th align="center" colspan="3" rowspan="1">Relative Effects of Treatment Y Compared with
                X<hr/></th>
            </tr>
            <tr>
              <th align="left" colspan="1" rowspan="1">X</th>
              <th align="center" colspan="1" rowspan="1">Y</th>
              <th align="center" colspan="1" rowspan="1"><inline-formula id="inline-formula1-0272989X13487604">
                  <mml:math display="inline" id="math1-0272989X13487604" overflow="scroll">
                    <mml:mover accent="true">
                      <mml:mi>x</mml:mi>
                      <mml:mo>¯</mml:mo>
                    </mml:mover>
                  </mml:math>
                </inline-formula></th>
              <th align="center" colspan="1" rowspan="1"><italic>s</italic></th>
              <th align="center" colspan="1" rowspan="1">95% CrI</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td colspan="1" rowspan="1">Placebo</td>
              <td colspan="1" rowspan="1">Pramipexole</td>
              <td colspan="1" rowspan="1">−1.81</td>
              <td colspan="1" rowspan="1">0.33</td>
              <td colspan="1" rowspan="1">−2.46, −1.16</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Placebo</td>
              <td colspan="1" rowspan="1">Ropinirole</td>
              <td colspan="1" rowspan="1">−0.47</td>
              <td colspan="1" rowspan="1">0.49</td>
              <td colspan="1" rowspan="1">−1.43, 0.49</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Placebo</td>
              <td colspan="1" rowspan="1">Bromocriptine</td>
              <td colspan="1" rowspan="1">−0.52</td>
              <td colspan="1" rowspan="1">0.48</td>
              <td colspan="1" rowspan="1">−1.46, 0.43</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Placebo</td>
              <td colspan="1" rowspan="1">Cabergoline</td>
              <td colspan="1" rowspan="1">−0.82</td>
              <td colspan="1" rowspan="1">0.52</td>
              <td colspan="1" rowspan="1">−1.84, 0.22</td>
            </tr>
            <tr>
              <th colspan="1" rowspan="1"/>
              <th colspan="1" rowspan="1"/>
              <th align="center" colspan="3" rowspan="1">Absolute Treatment Effects<hr/></th>
            </tr>
            <tr>
              <th colspan="1" rowspan="1"/>
              <th colspan="1" rowspan="1"/>
              <th align="center" colspan="1" rowspan="1"><inline-formula id="inline-formula2-0272989X13487604">
                  <mml:math display="inline" id="math2-0272989X13487604" overflow="scroll">
                    <mml:mover accent="true">
                      <mml:mi>x</mml:mi>
                      <mml:mo>¯</mml:mo>
                    </mml:mover>
                  </mml:math>
                </inline-formula></th>
              <th align="center" colspan="1" rowspan="1"><italic>s</italic></th>
              <th align="center" colspan="1" rowspan="1">95% CrI</th>
            </tr>
            <tr>
              <td colspan="2" rowspan="1">Placebo</td>
              <td colspan="1" rowspan="1">−0.73</td>
              <td colspan="1" rowspan="1">0.22</td>
              <td colspan="1" rowspan="1">−1.16, −0.30</td>
            </tr>
            <tr>
              <td colspan="2" rowspan="1">Pramipexole</td>
              <td colspan="1" rowspan="1">−2.54</td>
              <td colspan="1" rowspan="1">0.40</td>
              <td colspan="1" rowspan="1">−3.32, −1.76</td>
            </tr>
            <tr>
              <td colspan="2" rowspan="1">Ropinirole</td>
              <td colspan="1" rowspan="1">−1.21</td>
              <td colspan="1" rowspan="1">0.53</td>
              <td colspan="1" rowspan="1">−2.25, −0.15</td>
            </tr>
            <tr>
              <td colspan="2" rowspan="1">Bromocriptine</td>
              <td colspan="1" rowspan="1">−1.25</td>
              <td colspan="1" rowspan="1">0.53</td>
              <td colspan="1" rowspan="1">−2.28, −0.21</td>
            </tr>
            <tr>
              <td colspan="2" rowspan="1">Cabergoline</td>
              <td colspan="1" rowspan="1">−1.55</td>
              <td colspan="1" rowspan="1">0.57</td>
              <td colspan="1" rowspan="1">−2.66, −0.43</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Another format (<xref ref-type="table" rid="table4-0272989X13487604">Table 4</xref>) allows
        investigators to contrast results of pairwise meta-analyses with the results of the NMA.
        Although this table does not constitute a formal analysis of inconsistency in the
            network,<sup><xref ref-type="bibr" rid="bibr12-0272989X13487604">12</xref></sup> if the
        direct estimates are very close to their network counterparts, there may be no need to
        proceed with further consideration of inconsistency. Similarly, graphical displays that
        summarize the results in the tables can be presented (<xref ref-type="fig" rid="fig4-0272989X13487604">Figure 4</xref>). The draft of the 2013 methods
            guide<sup><xref ref-type="bibr" rid="bibr4-0272989X13487604">4</xref></sup> also
        emphasizes the use of forest plots to examine agreement between the direct and indirect
        estimates of treatment effects, which could be generated through node-splitting
            methods.<sup><xref ref-type="bibr" rid="bibr26-0272989X13487604">26</xref></sup></p>
      <table-wrap id="table4-0272989X13487604" position="float">
        <label>Table 4</label>
        <caption>
          <p>Parkinson’s example<sup><xref ref-type="bibr" rid="bibr34-0272989X13487604">34</xref></sup>: Posterior Mean (), Standard Deviation (<italic>s</italic>), and 95%
            Credible Interval (CrI) of the Relative Effect of Treatment Y Compared with X for All
            Possible Treatment Comparisons, for the Network Meta-analysis and Separate Pairwise
            Meta-analyses with Fixed Effects</p>
        </caption>
        <graphic alt-version="no" alternate-form-of="table4-0272989X13487604" position="float" xlink:href="10.1177_0272989X13487604-table4.tif" xlink:type="simple"/>
        <table>
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th colspan="1" rowspan="1"/>
              <th colspan="1" rowspan="1"/>
              <th align="center" colspan="3" rowspan="1">Network Meta-analysis<hr/></th>
              <th align="center" colspan="3" rowspan="1">Pairwise Meta-analyses<hr/></th>
            </tr>
            <tr>
              <th align="left" colspan="1" rowspan="1">X</th>
              <th align="center" colspan="1" rowspan="1">Y</th>
              <th align="center" colspan="1" rowspan="1"><inline-formula id="inline-formula3-0272989X13487604">
                  <mml:math display="inline" id="math3-0272989X13487604" overflow="scroll">
                    <mml:mover accent="true">
                      <mml:mi>x</mml:mi>
                      <mml:mo>¯</mml:mo>
                    </mml:mover>
                  </mml:math>
                </inline-formula></th>
              <th align="center" colspan="1" rowspan="1"><italic>s</italic></th>
              <th align="center" colspan="1" rowspan="1">95% CrI</th>
              <th align="center" colspan="1" rowspan="1"><inline-formula id="inline-formula4-0272989X13487604">
                  <mml:math display="inline" id="math4-0272989X13487604" overflow="scroll">
                    <mml:mover accent="true">
                      <mml:mi>x</mml:mi>
                      <mml:mo>¯</mml:mo>
                    </mml:mover>
                  </mml:math>
                </inline-formula></th>
              <th align="center" colspan="1" rowspan="1"><italic>s</italic></th>
              <th align="center" colspan="1" rowspan="1">95% CrI</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td colspan="1" rowspan="1">Placebo</td>
              <td colspan="1" rowspan="1">Pramipexole</td>
              <td colspan="1" rowspan="1">−1.81</td>
              <td colspan="1" rowspan="1">0.33</td>
              <td colspan="1" rowspan="1">−2.46, −1.16</td>
              <td colspan="1" rowspan="1">−1.83</td>
              <td colspan="1" rowspan="1">0.34</td>
              <td colspan="1" rowspan="1">−2.49, −1.17</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Placebo</td>
              <td colspan="1" rowspan="1">Ropinirole</td>
              <td colspan="1" rowspan="1">−0.47</td>
              <td colspan="1" rowspan="1">0.49</td>
              <td colspan="1" rowspan="1">−1.43, 0.49</td>
              <td colspan="1" rowspan="1">−0.31</td>
              <td colspan="1" rowspan="1">0.67</td>
              <td colspan="1" rowspan="1">−1.62, 1.00</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Placebo</td>
              <td colspan="1" rowspan="1">Bromocriptine</td>
              <td colspan="1" rowspan="1">−0.52</td>
              <td colspan="1" rowspan="1">0.48</td>
              <td colspan="1" rowspan="1">−1.46, 0.43</td>
              <td colspan="1" rowspan="1">−0.90</td>
              <td colspan="1" rowspan="1">0.69</td>
              <td colspan="1" rowspan="1">−2.26, 0.46</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Placebo</td>
              <td colspan="1" rowspan="1">Cabergoline</td>
              <td colspan="1" rowspan="1">−0.82</td>
              <td colspan="1" rowspan="1">0.52</td>
              <td colspan="1" rowspan="1">−1.84, 0.22</td>
              <td align="center" colspan="1" rowspan="1">—</td>
              <td align="center" colspan="1" rowspan="1">—</td>
              <td align="center" colspan="1" rowspan="1">—</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Pramipexole</td>
              <td colspan="1" rowspan="1">Ropinirole</td>
              <td colspan="1" rowspan="1">1.34</td>
              <td colspan="1" rowspan="1">0.54</td>
              <td colspan="1" rowspan="1">0.28, 2.41</td>
              <td align="center" colspan="1" rowspan="1">—</td>
              <td align="center" colspan="1" rowspan="1">—</td>
              <td align="center" colspan="1" rowspan="1">—</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Pramipexole</td>
              <td colspan="1" rowspan="1">Bromocriptine</td>
              <td colspan="1" rowspan="1">1.29</td>
              <td colspan="1" rowspan="1">0.52</td>
              <td colspan="1" rowspan="1">0.27, 2.32</td>
              <td colspan="1" rowspan="1">1.40</td>
              <td colspan="1" rowspan="1">0.70</td>
              <td colspan="1" rowspan="1">0.03, 2.77</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Pramipexole</td>
              <td colspan="1" rowspan="1">Cabergoline</td>
              <td colspan="1" rowspan="1">0.99</td>
              <td colspan="1" rowspan="1">0.56</td>
              <td colspan="1" rowspan="1">−0.10, 2.10</td>
              <td align="center" colspan="1" rowspan="1">—</td>
              <td align="center" colspan="1" rowspan="1">—</td>
              <td align="center" colspan="1" rowspan="1">—</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Ropinirole</td>
              <td colspan="1" rowspan="1">Bromocriptine</td>
              <td colspan="1" rowspan="1">−0.04</td>
              <td colspan="1" rowspan="1">0.32</td>
              <td colspan="1" rowspan="1">−0.68, 0.59</td>
              <td colspan="1" rowspan="1">0.00</td>
              <td colspan="1" rowspan="1">0.35</td>
              <td colspan="1" rowspan="1">−0.68, 0.68</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Ropinirole</td>
              <td colspan="1" rowspan="1">Cabergoline</td>
              <td colspan="1" rowspan="1">−0.34</td>
              <td colspan="1" rowspan="1">0.38</td>
              <td colspan="1" rowspan="1">−1.10, 0.41</td>
              <td align="center" colspan="1" rowspan="1">—</td>
              <td align="center" colspan="1" rowspan="1">—</td>
              <td align="center" colspan="1" rowspan="1">—</td>
            </tr>
            <tr>
              <td colspan="1" rowspan="1">Bromocriptine</td>
              <td colspan="1" rowspan="1">Cabergoline</td>
              <td colspan="1" rowspan="1">−0.30</td>
              <td colspan="1" rowspan="1">0.21</td>
              <td colspan="1" rowspan="1">−0.71, 0.11</td>
              <td colspan="1" rowspan="1">−0.30</td>
              <td colspan="1" rowspan="1">0.21</td>
              <td colspan="1" rowspan="1">−0.71, 0.11</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <fig id="fig4-0272989X13487604" position="float">
        <label>Figure 4</label>
        <caption>
          <p>Mean lost work-time reduction on treatments for Parkinson’s disease relative to
            placebo. The horizontal lines represent the 95% credible intervals with the dot
            representing the posterior mean relative treatment effect. The vertical line represents
            no treatment effect.</p>
        </caption>
        <graphic alt-version="no" position="float" xlink:href="10.1177_0272989X13487604-fig4.tif" xlink:type="simple"/>
      </fig>
      <p>A number of authors tabulate the probability that each treatment is most effective, which
        is an output available from Bayesian or other simulation-based approaches. This should be
        treated with great caution, particularly when there are many treatment alternatives. A
        treatment whose mean effect ranks quite low may still have a high probability of being best
        if there is relatively more uncertainty in its mean effect. This is misleading because for a
        given set of expected (mean) treatment effects, greater uncertainty may flatter a treatment.
        Differences between treatments in probability of being best of less than 90% cannot be given
        much credence. A more reliable indicator is a plot of the rankings of each treatment, or
        “rankograms.” When there are multiple outcomes (e.g., remission, relapse, discontinuation
        due to side effects), separate rankograms for each treatment, plotting the ranks on each
        outcome, can be very informative.<sup><xref ref-type="bibr" rid="bibr27-0272989X13487604">27</xref>,<xref ref-type="bibr" rid="bibr28-0272989X13487604">28</xref></sup> Other
        graphical presentations of results that are useful in different circumstances have been
            suggested.<sup><xref ref-type="bibr" rid="bibr29-0272989X13487604">29</xref></sup></p>
    </sec>
    <sec id="section14-0272989X13487604" sec-type="conclusions">
      <title>Conclusion</title>
      <p>As far as we know, an overall account of evidence synthesis has not been attempted before.
        In this series of papers we present a single framework that covers fixed and random effects
        models, in which pairwise meta-analysis, indirect comparisons, and 2-arm trials are special
        cases of networks, and indeed of multiarm trials, and in which outcomes expressed in several
        different reporting formats can be analyzed without recourse to normal approximations that
        are known to be problematic.<sup><xref ref-type="bibr" rid="bibr30-0272989X13487604">30</xref></sup> Although the tutorials in this series conform to a set of principles
        and requirements originating from NICE’s decision-making process, many of these
        principles—accountability, fairness, transparency—are desirable in all evidence synthesis
        and decision-making settings. Therefore, we hope that these papers will be useful for a far
        wider community in medical decision making.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>The authors thank Jenny Dunn at NICE DSU and Julian Higgins, Alec Miners, Georgia Salanti,
        Mike Spencer, and the team at NICE, led by Janet Robertson, for reviewing earlier versions
        of this paper, as well as reviewers at MDM for many useful suggestions.</p>
    </ack>
    <fn-group>
      <fn fn-type="financial-disclosure">
        <p>This series of tutorial papers was based on Technical Support Documents in Evidence
          Synthesis (available from <ext-link ext-link-type="uri" xlink:href="http://www.nicedsu.org.uk" xlink:type="simple">http://www.nicedsu.org.uk</ext-link>), which were
          prepared with funding from the NICE Decision Support Unit. The views, and any errors or
          omissions, expressed in this document are of the authors only.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="bibr1-0272989X13487604">
        <label>1.</label>
        <citation citation-type="web" xlink:type="simple">
          <collab xlink:type="simple">National Institute for Health and Clinical Excellence</collab>.
            <article-title>Guide to the single technology appraisal (STA) process</article-title>.
            <month>September</month>
          <year>2009</year>. Available from: URL: <ext-link ext-link-type="uri" xlink:href="http://www.nice.org.uk/media/42D/B3/STAGuideLrFinal.pdf" xlink:type="simple">http://www.nice.org.uk/media/42D/B3/STAGuideLrFinal.pdf</ext-link>
        </citation>
      </ref>
      <ref id="bibr2-0272989X13487604">
        <label>2.</label>
        <citation citation-type="web" xlink:type="simple">
          <collab xlink:type="simple">National Institute for Health and Clinical Excellence</collab>.
            <article-title>Guide to the multiple technology appraisal process (reference
            N2022)</article-title>. <month>September</month>
          <year>2009</year>. Available from: URL: <ext-link ext-link-type="uri" xlink:href="http://www.nice.org.uk/media/42D/8C/MTAGuideLRFINAL.pdf" xlink:type="simple">http://www.nice.org.uk/media/42D/8C/MTAGuideLRFINAL.pdf</ext-link>
        </citation>
      </ref>
      <ref id="bibr3-0272989X13487604">
        <label>3.</label>
        <citation citation-type="web" xlink:type="simple">
          <collab xlink:type="simple">National Institute for Health and Clinical Excellence</collab>.
            <article-title>Guide to the methods of technology appraisal (updated June
            2008)</article-title>. Available from: URL: <ext-link ext-link-type="uri" xlink:href="http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf" xlink:type="simple">http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf</ext-link>
        </citation>
      </ref>
      <ref id="bibr4-0272989X13487604">
        <label>4.</label>
        <citation citation-type="web" xlink:type="simple">
          <collab xlink:type="simple">National Institute for Health and Clinical Excellence</collab>.
            <article-title>Guide to the methods of technology appraisal, third edition: draft for
            consultation</article-title>. <year>2012</year>. Available from: URL: <ext-link ext-link-type="uri" xlink:href="http://www.nice.org.uk/media/CB1/43/GuideToMethodsOfTechnologyAppraisal2012.pdf" xlink:type="simple">http://www.nice.org.uk/media/CB1/43/GuideToMethodsOfTechnologyAppraisal2012.pdf</ext-link>
        </citation>
      </ref>
      <ref id="bibr5-0272989X13487604">
        <label>5.</label>
        <citation citation-type="book" xlink:type="simple">
          <collab xlink:type="simple">National Institute for Health and Clinical Excellence</collab>. <article-title>The
            Guidelines Manual</article-title>. <publisher-loc>London</publisher-loc>:
            <publisher-name>National Institute for Health and Clinical Excellence</publisher-name>;
            <year>2009</year>.</citation>
      </ref>
      <ref id="bibr6-0272989X13487604">
        <label>6.</label>
        <citation citation-type="web" xlink:type="simple">
          <collab xlink:type="simple">National Institute for Health and Clinical Excellence</collab>. <article-title>The
            Guidelines Manual</article-title>. <publisher-loc>London</publisher-loc>:
            <publisher-name>National Institute of Health and Clinical Excellence</publisher-name>;
            <year>2012</year>. Available from: URL <ext-link ext-link-type="uri" xlink:href="http://publications.nice.org.uk/the-guidelines-manual-pmg6" xlink:type="simple">http://publications.nice.org.uk/the-guidelines-manual-pmg6</ext-link>
        </citation>
      </ref>
      <ref id="bibr7-0272989X13487604">
        <label>7.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Sutton</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Cooper</surname>
              <given-names>N</given-names>
            </name>
            <name name-style="western">
              <surname>Goodacre</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Stevenson</surname>
              <given-names>M</given-names>
            </name>
          </person-group>. <article-title>Integration of meta-analysis and economic decision
            modeling for evaluating diagnostic tests</article-title>. <source>Med Decis
            Making</source>.
            <year>2008</year>;<volume>28</volume>(<issue>5</issue>):<fpage>650</fpage>–<lpage>67</lpage>.</citation>
      </ref>
      <ref id="bibr8-0272989X13487604">
        <label>8.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Ades</surname>
              <given-names>AE</given-names>
            </name>
            <name name-style="western">
              <surname>Sutton</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>. <article-title>Multiparameter evidence synthesis in epidemiology and
            medical decision making: current approaches</article-title>. <source>J R Stat Soc Ser A
            Stat Soc</source>.
            <year>2006</year>;<volume>169</volume>(<issue>1</issue>):<fpage>5</fpage>–<lpage>35</lpage>.</citation>
      </ref>
      <ref id="bibr9-0272989X13487604">
        <label>9.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>van Valkenhoef</surname>
              <given-names>G</given-names>
            </name>
            <name name-style="western">
              <surname>Tervonen</surname>
              <given-names>T</given-names>
            </name>
            <name name-style="western">
              <surname>Zhao</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>de Brock</surname>
              <given-names>B</given-names>
            </name>
            <name name-style="western">
              <surname>Hillege</surname>
              <given-names>H</given-names>
            </name>
            <name name-style="western">
              <surname>Postmus</surname>
              <given-names>D</given-names>
            </name>
          </person-group>. <article-title>Multi-criteria benefit-risk assessment using network
            meta-analysis</article-title>. <source>J Clin Epidemiol</source>.
            <year>2012</year>;<volume>65</volume>:<fpage>394</fpage>–<lpage>403</lpage>.</citation>
      </ref>
      <ref id="bibr10-0272989X13487604">
        <label>10.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Dias</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Sutton</surname>
              <given-names>AJ</given-names>
            </name>
            <name name-style="western">
              <surname>Ades</surname>
              <given-names>AE</given-names>
            </name>
            <name name-style="western">
              <surname>Welton</surname>
              <given-names>NJ</given-names>
            </name>
          </person-group>. <article-title>Evidence synthesis for decision making 2: a generalised
            linear modeling framework for pairwise and network meta-analysis of randomised
            controlled trials</article-title>. <source>Med Decis Making</source>.
            <year>2013</year>;<volume>33</volume>(<issue>5</issue>):<fpage>607</fpage>-<lpage>617</lpage>.</citation>
      </ref>
      <ref id="bibr11-0272989X13487604">
        <label>11.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Dias</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Sutton</surname>
              <given-names>AJ</given-names>
            </name>
            <name name-style="western">
              <surname>Welton</surname>
              <given-names>NJ</given-names>
            </name>
            <name name-style="western">
              <surname>Ades</surname>
              <given-names>AE</given-names>
            </name>
          </person-group>. <article-title>Evidence synthesis for decision making 3:
            heterogeneity–subgroups, meta-regression, bias and bias-adjustment</article-title>.
            <source>Med Decis Making</source>.
            <year>2013</year>;<volume>33</volume>(<issue>5</issue>):<fpage>618</fpage>-<lpage>640</lpage>.</citation>
      </ref>
      <ref id="bibr12-0272989X13487604">
        <label>12.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Dias</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Welton</surname>
              <given-names>NJ</given-names>
            </name>
            <name name-style="western">
              <surname>Sutton</surname>
              <given-names>AJ</given-names>
            </name>
            <name name-style="western">
              <surname>Caldwell</surname>
              <given-names>DM</given-names>
            </name>
            <name name-style="western">
              <surname>Lu</surname>
              <given-names>G</given-names>
            </name>
            <name name-style="western">
              <surname>Ades</surname>
              <given-names>AE</given-names>
            </name>
          </person-group>. <article-title>Evidence synthesis for decision making 4: inconsistency in
            networks of evidence based on randomised controlled trials</article-title>. <source>Med
            Decis Making</source>.
            <year>2013</year>;<volume>33</volume>(<issue>5</issue>):<fpage>641</fpage>-<lpage>656</lpage>.</citation>
      </ref>
      <ref id="bibr13-0272989X13487604">
        <label>13.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Lunn</surname>
              <given-names>D</given-names>
            </name>
            <name name-style="western">
              <surname>Spiegelhalter</surname>
              <given-names>D</given-names>
            </name>
            <name name-style="western">
              <surname>Thomas</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Best</surname>
              <given-names>N</given-names>
            </name>
          </person-group>. <article-title>The BUGS project: evolution, critique and future
            directions</article-title>. <source>Stat Med</source>.
            <year>2009</year>;<volume>28</volume>:<fpage>3049</fpage>–<lpage>67</lpage>.</citation>
      </ref>
      <ref id="bibr14-0272989X13487604">
        <label>14.</label>
        <citation citation-type="web" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Spiegelhalter</surname>
              <given-names>D</given-names>
            </name>
            <name name-style="western">
              <surname>Thomas</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Best</surname>
              <given-names>N</given-names>
            </name>
            <name name-style="western">
              <surname>Lunn</surname>
              <given-names>D</given-names>
            </name>
          </person-group>. <article-title>WinBUGS user manual version 1.4 January
            2003</article-title>. Upgraded to version 1.4.32007. Available from: URL: <ext-link ext-link-type="uri" xlink:href="http://www.mrc-bsu.cam.ac.uk/bugs" xlink:type="simple">http://www.mrc-bsu.cam.ac.uk/bugs</ext-link>
        </citation>
      </ref>
      <ref id="bibr15-0272989X13487604">
        <label>15.</label>
        <citation citation-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Congdon</surname>
              <given-names>P</given-names>
            </name>
          </person-group>. <source>Bayesian Statistical Modeling</source>.
            <publisher-loc>Chichester, UK</publisher-loc>: <publisher-name>Wiley</publisher-name>;
            <year>2001</year>.</citation>
      </ref>
      <ref id="bibr16-0272989X13487604">
        <label>16.</label>
        <citation citation-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Welton</surname>
              <given-names>NJ</given-names>
            </name>
            <name name-style="western">
              <surname>Sutton</surname>
              <given-names>AJ</given-names>
            </name>
            <name name-style="western">
              <surname>Cooper</surname>
              <given-names>NJ</given-names>
            </name>
            <name name-style="western">
              <surname>Abrams</surname>
              <given-names>KR</given-names>
            </name>
            <name name-style="western">
              <surname>Ades</surname>
              <given-names>AE</given-names>
            </name>
          </person-group>. <source>Evidence Synthesis for Decision Making in Healthcare</source>.
            <publisher-loc>New York</publisher-loc>: <publisher-name>Wiley</publisher-name>;
            <year>2012</year>.</citation>
      </ref>
      <ref id="bibr17-0272989X13487604">
        <label>17.</label>
        <citation citation-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Spiegelhalter</surname>
              <given-names>DJ</given-names>
            </name>
            <name name-style="western">
              <surname>Abrams</surname>
              <given-names>KR</given-names>
            </name>
            <name name-style="western">
              <surname>Myles</surname>
              <given-names>J</given-names>
            </name>
          </person-group>. <source>Bayesian Approaches to Clinical Trials and Health-Care
            Evaluation</source>. <publisher-loc>New York</publisher-loc>:
            <publisher-name>Wiley</publisher-name>; <year>2004</year>.</citation>
      </ref>
      <ref id="bibr18-0272989X13487604">
        <label>18.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Dias</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Welton</surname>
              <given-names>NJ</given-names>
            </name>
            <name name-style="western">
              <surname>Sutton</surname>
              <given-names>AJ</given-names>
            </name>
            <name name-style="western">
              <surname>Ades</surname>
              <given-names>AE</given-names>
            </name>
          </person-group>. <article-title>Evidence synthesis for decision making 5: the baseline
            natural history model</article-title>. <source>Med Decis Making</source>.
            <year>2013</year>;<volume>33</volume>(<issue>5</issue>):<fpage>657</fpage>-<lpage>670</lpage>.</citation>
      </ref>
      <ref id="bibr19-0272989X13487604">
        <label>19.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Dias</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Sutton</surname>
              <given-names>AJ</given-names>
            </name>
            <name name-style="western">
              <surname>Welton</surname>
              <given-names>NJ</given-names>
            </name>
            <name name-style="western">
              <surname>Ades</surname>
              <given-names>AE</given-names>
            </name>
          </person-group>. <article-title>Evidence synthesis for decision making 6: embedding
            evidence synthesis in probabilistic cost-effectiveness analysis</article-title>.
            <source>Med Decis Making</source>.
            <year>2013</year>;<volume>33</volume>(<issue>5</issue>):<fpage>671</fpage>-<lpage>678</lpage>.</citation>
      </ref>
      <ref id="bibr20-0272989X13487604">
        <label>20.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Ades</surname>
              <given-names>AE</given-names>
            </name>
            <name name-style="western">
              <surname>Caldwell</surname>
              <given-names>DM</given-names>
            </name>
            <name name-style="western">
              <surname>Reken</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Welton</surname>
              <given-names>NJ</given-names>
            </name>
            <name name-style="western">
              <surname>Sutton</surname>
              <given-names>AJ</given-names>
            </name>
            <name name-style="western">
              <surname>Dias</surname>
              <given-names>S</given-names>
            </name>
          </person-group>. <article-title>Evidence synthesis for decision making 7: a reviewer’s
            checklist</article-title>. <source>Med Decis Making</source>.
            <year>2013</year>;<volume>33</volume>(<issue>5</issue>):<fpage>679</fpage>-<lpage>691</lpage>.</citation>
      </ref>
      <ref id="bibr21-0272989X13487604">
        <label>21.</label>
        <citation citation-type="web" xlink:type="simple">
          <collab xlink:type="simple">National Institute for Health and Clinical Excellence</collab>.
            <article-title>Social value judgements: principles for the development of NICE
            guidance</article-title>. <month>February</month>
          <year>2008</year>. Available from: URL: <ext-link ext-link-type="uri" xlink:href="http://www.nice.org.uk/media/C18/30/SVJ2PUBLICATION2008.pdf" xlink:type="simple">http://www.nice.org.uk/media/C18/30/SVJ2PUBLICATION2008.pdf</ext-link>
        </citation>
      </ref>
      <ref id="bibr22-0272989X13487604">
        <label>22.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Lumley</surname>
              <given-names>T</given-names>
            </name>
          </person-group>. <article-title>Network meta-analysis for indirect treatment
            comparisons</article-title>. <source>Stat Med</source>.
            <year>2002</year>;<volume>21</volume>:<fpage>2313</fpage>–<lpage>24</lpage>.</citation>
      </ref>
      <ref id="bibr23-0272989X13487604">
        <label>23.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Batagelj</surname>
              <given-names>V</given-names>
            </name>
            <name name-style="western">
              <surname>Mrvar</surname>
              <given-names>A</given-names>
            </name>
          </person-group>. <article-title>Pajek—program for large network analysis</article-title>.
            <source>Connections</source>.
            <year>1998</year>;<volume>21</volume>(<issue>2</issue>):<fpage>47</fpage>–<lpage>57</lpage>.</citation>
      </ref>
      <ref id="bibr24-0272989X13487604">
        <label>24.</label>
        <citation citation-type="web" xlink:type="simple">
          <collab xlink:type="simple">R Development Core Team</collab>. <article-title>R: A Language and Environment for
            Statistical Computing. Vienna, Austria: R Foundation for Statistical
            Computing</article-title>; <year>2010</year>. Available from: URL: <ext-link ext-link-type="uri" xlink:href="http://www.R-project.org" xlink:type="simple">http://www.R-project.org</ext-link>
        </citation>
      </ref>
      <ref id="bibr25-0272989X13487604">
        <label>25.</label>
        <citation citation-type="web" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Salanti</surname>
              <given-names>G</given-names>
            </name>
          </person-group>. <article-title>Multiple-treatments meta-analysis of a network of
            interventions</article-title>. <year>2011</year>. Available from: URL: <ext-link ext-link-type="uri" xlink:href="http://www.mtm.uoi.gr/" xlink:type="simple">http://www.mtm.uoi.gr/</ext-link>
        </citation>
      </ref>
      <ref id="bibr26-0272989X13487604">
        <label>26.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Dias</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Welton</surname>
              <given-names>NJ</given-names>
            </name>
            <name name-style="western">
              <surname>Caldwell</surname>
              <given-names>DM</given-names>
            </name>
            <name name-style="western">
              <surname>Ades</surname>
              <given-names>AE</given-names>
            </name>
          </person-group>. <article-title>Checking consistency in mixed treatment comparison
            meta-analysis</article-title>. <source>Stat Med</source>.
            <year>2010</year>;<volume>29</volume>:<fpage>932</fpage>–<lpage>44</lpage>.</citation>
      </ref>
      <ref id="bibr27-0272989X13487604">
        <label>27.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Cipriani</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Furukawa</surname>
              <given-names>TA</given-names>
            </name>
            <name name-style="western">
              <surname>Salanti</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>. <article-title>Comparative efficacy and acceptability of 12 new
            generation antidepressants: a multiple-treatments meta-analysis</article-title>.
            <source>Lancet</source>.
            <year>2009</year>;<volume>373</volume>:<fpage>746</fpage>–<lpage>58</lpage>.</citation>
      </ref>
      <ref id="bibr28-0272989X13487604">
        <label>28.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Ades</surname>
              <given-names>AE</given-names>
            </name>
            <name name-style="western">
              <surname>Mavranezouli</surname>
              <given-names>I</given-names>
            </name>
            <name name-style="western">
              <surname>Dias</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Welton</surname>
              <given-names>NJ</given-names>
            </name>
            <name name-style="western">
              <surname>Whittington</surname>
              <given-names>C</given-names>
            </name>
            <name name-style="western">
              <surname>Kendall</surname>
              <given-names>T</given-names>
            </name>
          </person-group>. <article-title>Network meta-analysis with competing risk
            outcomes</article-title>. <source>Value Health</source>.
            <year>2010</year>;<volume>13</volume>(<issue>8</issue>):<fpage>976</fpage>–<lpage>83</lpage>.</citation>
      </ref>
      <ref id="bibr29-0272989X13487604">
        <label>29.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Salanti</surname>
              <given-names>G</given-names>
            </name>
            <name name-style="western">
              <surname>Ades</surname>
              <given-names>AE</given-names>
            </name>
            <name name-style="western">
              <surname>Ioannidis</surname>
              <given-names>JPA</given-names>
            </name>
          </person-group>. <article-title>Graphical methods and numerical summaries for presenting
            results from multiple-treatment meta-analysis: an overview and tutorial</article-title>.
            <source>J Clin Epidemiol</source>.
            <year>2011</year>;<volume>64</volume>:<fpage>163</fpage>–<lpage>71</lpage>.</citation>
      </ref>
      <ref id="bibr30-0272989X13487604">
        <label>30.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Sweeting</surname>
              <given-names>MJ</given-names>
            </name>
            <name name-style="western">
              <surname>Sutton</surname>
              <given-names>AJ</given-names>
            </name>
            <name name-style="western">
              <surname>Lambert</surname>
              <given-names>PC</given-names>
            </name>
          </person-group>. <article-title>What to add to nothing? Use and avoidance of continuity
            corrections in meta-analysis of sparse data</article-title>. <source>Stat Med</source>.
            <year>2004</year>;<volume>23</volume>:<fpage>1351</fpage>–<lpage>75</lpage>.</citation>
      </ref>
      <ref id="bibr31-0272989X13487604">
        <label>31.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Carlin</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>. <article-title>Meta-analysis for 2 x 2 tables: a Bayesian
            approach</article-title>. <source>Stat Med</source>.
            <year>1992</year>;<volume>11</volume>(<issue>2</issue>):<fpage>141</fpage>–<lpage>58</lpage>.</citation>
      </ref>
      <ref id="bibr32-0272989X13487604">
        <label>32.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Hooper</surname>
              <given-names>L</given-names>
            </name>
            <name name-style="western">
              <surname>Summerbell</surname>
              <given-names>CD</given-names>
            </name>
            <name name-style="western">
              <surname>Higgins</surname>
              <given-names>JPT</given-names>
            </name>
            <etal/>
          </person-group>. <article-title>Reduced or modified dietary fat for preventing
            cardiovascular disease</article-title>. <source>Cochrane Database Syst Rev</source>.
            <year>2000</year>;(<issue>2</issue>):CD002137.</citation>
      </ref>
      <ref id="bibr33-0272989X13487604">
        <label>33.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Elliott</surname>
              <given-names>WJ</given-names>
            </name>
            <name name-style="western">
              <surname>Meyer</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>. <article-title>Incident diabetes in clinical trials of antihypertensive
            drugs: a network meta-analysis</article-title>. <source>Lancet</source>.
            <year>2007</year>;<volume>369</volume>(<issue>9557</issue>):<fpage>201</fpage>–<lpage>7</lpage>.</citation>
      </ref>
      <ref id="bibr34-0272989X13487604">
        <label>34.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Franchini</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Dias</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Ades</surname>
              <given-names>AE</given-names>
            </name>
            <name name-style="western">
              <surname>Jansen</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Welton</surname>
              <given-names>N</given-names>
            </name>
          </person-group>. <article-title>Accounting for correlation in mixed treatment comparisons
            with multi-arm trials</article-title>. <source>Research Synthesis Methods</source>.
            <year>2012</year>;<volume>3</volume>:<fpage>142</fpage>–<lpage>60</lpage>.</citation>
      </ref>
      <ref id="bibr35-0272989X13487604">
        <label>35.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Woolacott</surname>
              <given-names>N</given-names>
            </name>
            <name name-style="western">
              <surname>Hawkins</surname>
              <given-names>NS</given-names>
            </name>
            <name name-style="western">
              <surname>Mason</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>. <article-title>Etanercept and efalizumab for the treatment of psoriasis:
            a systematic review</article-title>. <source>Health Technol Assess</source>.
            <year>2006</year>;<volume>10</volume>(<issue>46</issue>):<fpage>1</fpage>–<lpage>233</lpage>.</citation>
      </ref>
      <ref id="bibr36-0272989X13487604">
        <label>36.</label>
        <citation citation-type="book" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Sutton</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>. <article-title>Meta-analysis Methods for Combining Information from
            Different Sources Evaluating Health Interventions</article-title>:
            <publisher-loc>Leicester, UK</publisher-loc>: <publisher-name>University of
            Leicester</publisher-name>; <year>2002</year>.</citation>
      </ref>
      <ref id="bibr37-0272989X13487604">
        <label>37.</label>
        <citation citation-type="web" xlink:type="simple">
          <collab xlink:type="simple">National Institute for Health and Clinical Excellence</collab>.
            <article-title>Certolizumab pegol for the treatment of rheumatoid
            arthritis</article-title>. <year>2010</year>. Report no. TA186. Available from: URL:
            <ext-link ext-link-type="uri" xlink:href="http://guidance.nice.org.uk/TA186" xlink:type="simple">http://guidance.nice.org.uk/TA186</ext-link></citation>
      </ref>
      <ref id="bibr38-0272989X13487604">
        <label>38.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Hasselblad</surname>
              <given-names>V</given-names>
            </name>
          </person-group>. <article-title>Meta-analysis of multi-treatment studies</article-title>.
            <source>Med Decis Making</source>.
            <year>1998</year>;<volume>18</volume>:<fpage>37</fpage>–<lpage>43</lpage>.</citation>
      </ref>
      <ref id="bibr39-0272989X13487604">
        <label>39.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Lu</surname>
              <given-names>G</given-names>
            </name>
            <name name-style="western">
              <surname>Ades</surname>
              <given-names>A</given-names>
            </name>
          </person-group>. <article-title>Assessing evidence consistency in mixed treatment
            comparisons</article-title>. <source>J Am Stat Assoc</source>.
            <year>2006</year>;<volume>101</volume>:<fpage>447</fpage>–<lpage>59</lpage>.</citation>
      </ref>
      <ref id="bibr40-0272989X13487604">
        <label>40.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Boland</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Dundar</surname>
              <given-names>Y</given-names>
            </name>
            <name name-style="western">
              <surname>Bagust</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>. <article-title>Early thrombolysis for the treatment of acute myocardial
            infarction: a systematic review and economic evaluation</article-title>. <source>Health
            Technol Assess</source>.
            <year>2003</year>;<volume>7</volume>(<issue>15</issue>):<fpage>1</fpage>–<lpage>136</lpage>.</citation>
      </ref>
      <ref id="bibr41-0272989X13487604">
        <label>41.</label>
        <citation citation-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Keeley</surname>
              <given-names>EC</given-names>
            </name>
            <name name-style="western">
              <surname>Boura</surname>
              <given-names>JA</given-names>
            </name>
            <name name-style="western">
              <surname>Grines</surname>
              <given-names>CL</given-names>
            </name>
          </person-group>. <article-title>Primary angioplasty versus intravenous thrombolytic
            therapy for acute myocardial infarction: a quantitative review of 23 randomised
            trials</article-title>. <source>Lancet</source>.
            <year>2003</year>;<volume>361</volume>:<fpage>13</fpage>–<lpage>20</lpage>.</citation>
      </ref>
    </ref-list>
  </back>
</article>